earnings

jnj/tibotec 4q earnings just released
Prezista hits $600M per year after 2-3 yrs.

gilead 4q earnings...
Atripla sales increased 50 percent to $697.8 million for the fourth quarter of 2009
Truvada sales increased 19 percent to $670.7 million for the fourth quarter of 2009
Viread(R) (tenofovir disoproxil fumarate) sales increased 10 percent to $178.3 million for the fourth quarter of 2009

so for tenofovir, 1/3 $697M + 1/2 $670M + $178M = $745M PER QTR! or almost $3B /yr

Now, as a better drug, that's what ATC should be aiming for...!


and a new application/income

New drug combo prevents HIV/AIDS

Tue, 26 Jan 2010 17:31:03 GMT

A new drug combo, consisting of medications commonly used to fight HIV/AIDS, has shown promising results in protecting individuals against the disease.

According to a study published in PloS One, Truvada, a combination of tenofovir and emtricitabine, prevents HIV infection through major routes of transmission in mice with "humanized" immune systems.

The drug is believed to produce pre-exposure prophylaxis (PrEP) through preventing the virus from creating more viruses in the body.

Scientists hope their finding will help save many individuals from becoming infected with the life-threatening disease.

They believe the drug can also be used to prevent possible infection commonly reported in healthcare providers after being pricked by possibly contaminated needles.

"One single pill once a day, totally available in the pharmacy for patients, can be used to prevent transmission by any mode anywhere in the world," said lead researcher J. Victor Garcia-Martinez.